BACH1 is upregulated in MM patients, and those in the high‐expression BACH1 group have a better prognosis after Btz‐treatment.[450] Therefore, functionally upregulating BACH1 is a potential anti‐leukemia and MM treatment strategy. This evidence concerns the gene BACH1 and Miyoshi myopathy.